After activation by its ligands, GPR109A can significantly inhibit the body’s inflammatory response in different diseases such as atherosclerosis, obesity, sepsis, diabetes, colitis, and neurodegenerative diseases (10). The gene discussed is HCAR2; the disease is obesity due to melanocortin 4 receptor deficiency.